A61K 39/39533
Against materials from animals
Official title: {against materials from animals}
A61K39/39533 (Against materials from animals) appears on 9,291 US grants and 18,877 published applications in this corpus.
Search patents in A61K- Granted patents
- 9,291
- Published applications
- 18,877
- Assignees
- 4,185
- Inventors
- 24,152
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 2 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 2 | 0 |
| 1992 | 2 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 4 | 0 |
| 1996 | 3 | 0 |
| 1997 | 8 | 0 |
| 1998 | 17 | 0 |
| 1999 | 8 | 0 |
| 2000 | 16 | 0 |
| 2001 | 19 | 14 |
| 2002 | 24 | 84 |
| 2003 | 18 | 116 |
| 2004 | 24 | 128 |
| 2005 | 18 | 154 |
| 2006 | 41 | 183 |
| 2007 | 57 | 187 |
| 2008 | 60 | 242 |
| 2009 | 93 | 355 |
| 2010 | 129 | 430 |
| 2011 | 171 | 515 |
| 2012 | 219 | 544 |
| 2013 | 357 | 959 |
| 2014 | 466 | 1122 |
| 2015 | 586 | 1030 |
| 2016 | 618 | 1133 |
| 2017 | 681 | 1184 |
| 2018 | 599 | 1261 |
| 2019 | 727 | 1241 |
| 2020 | 762 | 1328 |
| 2021 | 725 | 1411 |
| 2022 | 671 | 1354 |
| 2023 | 580 | 1191 |
| 2024 | 596 | 1104 |
| 2025 | 600 | 904 |
| 2026 | 385 | 703 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Anti-Claudin18.2 antigen-binding fragment or antibody, and use thereof182551196 Oct 2026US 12,751,972 B2Guangzhou Bio-Gene Technology Co., Ltd
- Compositions and methods of treating lupus nephritis6 Oct 2026US 12,752,005 B2Genentech, Inc.
- Antibodies binding to alpha-synuclein for therapy and diagnosis6 Oct 2026US 12,753,223 B2AC Immune SA
- TGFbeta1-binding immunoglobulins and use thereof6 Oct 2026US 12,753,226 B2Scholar Rock, Inc.
- Camptothecin derivatives29 Sep 2026US 12,747,250 B2ImmunoGen, Inc.
- Compositions and methods for treating cancer by targeting bach18 Oct 2026US 2026/0306455 A1
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Pharmaceutical combination for cancer treatment8 Oct 2026US 2026/0306466 A1Miyarisan Pharmaceutical Co., Ltd.
- Inhaled statins as bronchodilators to improve lung function in respiratory diseases8 Oct 2026US 2026/0306477 A1Beth Israel Deaconess Medical Center, Inc.
- Inverse agonists of rar related orphan receptors (rors)8 Oct 2026US 2026/0306484 A111949098 CANADA INC. (NUREDCO) c/o Jean I. TCHERVENKOV
Most cited
By later US patents
- Interleukin-1α antibodies1,029US 8,034,337 B2Xbiotech, Inc. · 2011
- Antigen-adjuvant compositions and methods1,024US 8,790,658 B2Sanofi Pasteur Limited · 2014
- Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics940US 8,008,449 B2Medarex, Inc. · 2011
- Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation733US 9,101,621 B2Celgene Corporation · 2015
- Anti-PD-L1 antibodies, compositions and articles of manufacture459US 8,217,149 B2Genentech, Inc. · 2012